ANRO
Alto Neuroscience, Inc.NYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$719.73M
P/E Ratio
—
EPS
$-2.19
Beta
2.06
52W High
$25.17
52W Low
$1.90
50-Day MA
$19.30
200-Day MA
$11.18
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company is headquartered in Los Altos, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-65.70M |
| Operating Margin | 0.00% |
| Return on Equity | -41.80% |
| Return on Assets | -22.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.74 |
| Price-to-Book | 4.58 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $31.95M |
| Float | $19.15M |
| % Insiders | 6.25% |
| % Institutions | 77.03% |
Analyst Ratings
Consensus ($35.24 target)
9
Buy1
HoldData last updated: 4/7/2026